AHB(SH:688639) Ge Long Hui A P P·2026-02-27 09:48Core Viewpoint - Huaheng Biological (688639.SH) expects a revenue increase of 32.50% to 2.886 billion yuan for the fiscal year 2025, while net profit attributable to shareholders is projected to decrease by 30.97% to 131 million yuan [1] Financial Performance - The company anticipates a revenue of 2.886 billion yuan for 2025, marking a year-on-year increase of 32.50% [1] - Net profit attributable to the parent company is expected to be 131 million yuan, reflecting a decrease of 30.97% compared to the previous year [1] - The net profit after deducting non-recurring gains and losses is projected to be 125 million yuan, down 29.63% year-on-year [1] Industry Context - The international external environment is complex, with European anti-dumping and U.S. tariff policies impacting the industry [1] - The amino acid and vitamin sectors are experiencing a phase of supply-demand imbalance, leading to intensified market competition [1] - The average prices of the company's main products, valine and myo-inositol, have decreased compared to the same period last year [1] Strategic Focus - The company is committed to its mission of "developing biotechnology and serving life and health," focusing on the implementation of core strategies [1] - New project industrialization is progressing steadily, and sales scale continues to expand [1] - Increased operational scale has led to a rise in various expenses compared to the previous year, contributing to the overall profit decline [1]